You are not logged in.

Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients

Fowler,RA, Mittmann,N, Geerts,W, Heels-Ansdell,D, Gould,MK, Guyatt,G, Krahn,M, Finfer,S, Pinto,R, Chan,B, Ormanidhi,O, Arabi,Y, Qushmaq,I, Rocha,MG, Dodek,P, McIntyre,L, Hall,R, Ferguson,ND, Mehta,S, Marshall,JC, Doig,CJ, Muscedere,J, Jacka,MJ, Klinger,JR, Vlahakis,N, Orford,N, Seppelt,I, Skrobik,YK, Sud,S, Cade,JF, Cooper,J and Cook,D 2014, Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients, JAMA: journal of the american medical association, vol. 312, no. 20, pp. 2135-2145, doi: 10.1001/jama.2014.15101.

Attached Files
Name Description MIMEType Size Downloads

Title Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients
Author(s) Fowler,RA
Mittmann,N
Geerts,W
Heels-Ansdell,D
Gould,MK
Guyatt,G
Krahn,M
Finfer,S
Pinto,R
Chan,B
Ormanidhi,O
Arabi,Y
Qushmaq,I
Rocha,MG
Dodek,P
McIntyre,L
Hall,R
Ferguson,ND
Mehta,S
Marshall,JC
Doig,CJ
Muscedere,J
Jacka,MJ
Klinger,JR
Vlahakis,N
Orford,N
Seppelt,I
Skrobik,YK
Sud,S
Cade,JF
Cooper,J
Cook,D
Journal name JAMA: journal of the american medical association
Volume number 312
Issue number 20
Start page 2135
End page 2145
Publisher American Medical Association
Place of publication Chicago, IL
Publication date 2014-11-26
ISSN 1538-3598
0098-7484
Keyword(s) Canadian Critical Care Trials Group
Australia and New Zealand Intensive Care Society Clinical Trials Group
Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
MOLECULAR-WEIGHT HEPARIN
DIRECT MEDICAL COSTS
INTENSIVE-CARE-UNIT
HOSPITALIZED-PATIENTS
CONFIDENCE-INTERVALS
ECONOMIC-EVALUATION
PROPHYLAXIS
VARIABILITY
THROMBOSIS
OUTCOMES
Summary Venous thromboembolism (VTE) is a common complication of acute illness, and its prevention is a ubiquitous aspect of inpatient care. A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin.
Language eng
DOI 10.1001/jama.2014.15101
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 929999 Health not elsewhere classified
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2014, American Medical Association
Persistent URL http://hdl.handle.net/10536/DRO/DU:30072011

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 18 times in TR Web of Science
Scopus Citation Count Cited 17 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 100 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Thu, 02 Apr 2015, 10:23:14 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.